Cargando…

Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells

Therapeutic agents aimed at inhibiting a single molecular target have not been successful in cancer therapy, but rather they impart resistance. However, multi-target inhibitors have shown promising results in circumventing the development of resistance and inducing apoptosis in cancer cells/tissues....

Descripción completa

Detalles Bibliográficos
Autor principal: Singh, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863640/
https://www.ncbi.nlm.nih.gov/pubmed/29593389
http://dx.doi.org/10.2147/IJN.S124701
_version_ 1783308421896863744
author Singh, Sanjay
author_facet Singh, Sanjay
author_sort Singh, Sanjay
collection PubMed
description Therapeutic agents aimed at inhibiting a single molecular target have not been successful in cancer therapy, but rather they impart resistance. However, multi-target inhibitors have shown promising results in circumventing the development of resistance and inducing apoptosis in cancer cells/tissues. In this study, we encapsulated doxorubicin and celecoxib in a single liposome at a ratio of 1:10. These dual drug-encapsulated liposomes showed excellent anticancer activity compared to individually encapsulated liposomes. The expression of key proteins such as AKT and COX-2 was suppressed, which suggests that doxorubicin and celecoxib synergistically inhibit multiple key signaling pathways.
format Online
Article
Text
id pubmed-5863640
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-58636402018-03-28 Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells Singh, Sanjay Int J Nanomedicine Short Report Therapeutic agents aimed at inhibiting a single molecular target have not been successful in cancer therapy, but rather they impart resistance. However, multi-target inhibitors have shown promising results in circumventing the development of resistance and inducing apoptosis in cancer cells/tissues. In this study, we encapsulated doxorubicin and celecoxib in a single liposome at a ratio of 1:10. These dual drug-encapsulated liposomes showed excellent anticancer activity compared to individually encapsulated liposomes. The expression of key proteins such as AKT and COX-2 was suppressed, which suggests that doxorubicin and celecoxib synergistically inhibit multiple key signaling pathways. Dove Medical Press 2018-03-15 /pmc/articles/PMC5863640/ /pubmed/29593389 http://dx.doi.org/10.2147/IJN.S124701 Text en © 2018 Singh. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Short Report
Singh, Sanjay
Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
title Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
title_full Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
title_fullStr Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
title_full_unstemmed Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
title_short Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
title_sort liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863640/
https://www.ncbi.nlm.nih.gov/pubmed/29593389
http://dx.doi.org/10.2147/IJN.S124701
work_keys_str_mv AT singhsanjay liposomeencapsulationofdoxorubicinandcelecoxibincombinationinhibitsprogressionofhumanskincancercells